Top 10 Evidence-Based Essentials in Dermatology

• by Conexiant News Staff

• April 24, 2026

FDA Expands Guselkumab Label in PsA

Phase 3b APEX findings support the addition of structural joint damage inhibition data to the prescribing information.

• by Kathryn Wighton

• May 29, 2026

• 2 min

Lymphocyte transformation test in pediatric drug hypersensitivity: case series report from a tertiary care hospital

• by Olga Rogozina, Susana Martín-López, Fiorela Cinthia Dueñas López, Zoraida del Solar Moreno, Larry Leiva Castrejon, Daniela Aguilar-Concepción, María Jiménez-González, Ana Martínez Feito, Miguel González-Muñoz, Elena Ramírez

• May 15, 2026

Integrated systems toxicology identifies TCDD-responsive targets linked to immune dysregulation and treatment response in psoriasis

• by Xuan Zhang, Yankun Zhang, Yanling He

• May 29, 2026